Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

Journal of Clinical Oncology

Volumn 32, Issue 13, 2014, Pages 1302-1308

  Pujade Lauraine, Eric ^a   Hilpert, Felix ^e   Weber, Béatrice ^b   Reuss, Alexander ^f   Poveda, Andres ^h   Kristensen, Gunnar ^j   Sorio, Roberto ^k   Vergote, Ignace ^l   Witteveen, Petronella ^m   Bamias, Aristotelis ⁿ   Pereira, Deolinda ^o   Wimberger, Pauline ^g   Oaknin, Ana ⁱ   Mirza, Mansoor Raza ^p   Follana, Philippe ^c   Bollag, David ^q   Ray Coquard, Isabelle ^d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d CENTRE LÉON BÉRARD   (France)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f AGO   (Germany)

^g UNIVERSITY OF DUISBURG ESSEN   (Germany)

^h INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁿ UNIVERSITY OF ATHENS   (Greece)

^o PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^p Rigshospitalet   (Denmark)

^q F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CHEMOTHERAPY INDUCED EMESIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FISTULA; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HYPERTENSION; INFARCTION; MAJOR CLINICAL STUDY; OPEN STUDY; OVARY CANCER; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SENSORY NEUROPATHY; STOMACH PERFORATION; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY; WOUND HEALING IMPAIRMENT; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; MIDDLE AGED; MULTICENTER STUDY; OVARY TUMOR; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; TOPOTECAN;

EID: 84899837376     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.4489     Document Type: Article

References (24)

1. Pujade-Lauraine E, Alexandre JL: Update of randomized trials in recurrent disease. Ann Oncol 22:viii61-viii64, 2011 (suppl 8)
2. Buda A, Floriani I, Rossi R, et al: Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: An Italian collaborative study from the Mario Negri Institute, Milan, GONO (Gruppo Oncologico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) group. Br J Cancer 90:2112-2117, 2004 (Pubitemid 38877624)
3. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001 (Pubitemid 32642183)
4. Vergote I, Finkler N, del Campo J, et al: ASSIST-1 study group: Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer Eur J Cancer 45:2324-2332, 2009
5. Mutch DG, Orlando M, Goss T, et al: Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811-2818, 2007 (Pubitemid 47123191)
6. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997 (Pubitemid 27251118)
7. Sehouli J, Stengel D, Oskay-Oezcelik G, et al: Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: Results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26:3176- 3182, 2008
8. Lortholary A, Largillier R, Weber B, et al: Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: The CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol 23:346-352, 2012
9. Naumann RW, Coleman RL: Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 71:1397-1412, 2011
10. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:5165-5171, 2007 (Pubitemid 350237599)
11. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007 (Pubitemid 350232248)
12. McGonigle KF, Muntz HG, Vuky J, et al: Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: Results of a phase 2 study. Cancer 117:3731-3740, 2011
13. Garcia AA, Hirte H, Fleming G, et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 26:76-82, 2008
14. Stockler MR, Hilpert F, Friedlander M, et al: Patient-reported outcome results from the openlabel phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 32:1309-1316, 2014
15. Kobold S, Hegewisch-Becker S, Oechsle K, et al: Intraperitoneal VEGF inhibition using bevacizumab: A potential approach for the symptomatic treatment of malignant ascites? Oncologist 14:1242-1251, 2009
16. Burger RA, Brady MF, Bookman MA, et al: Gynecologic Oncology Group: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473-2483, 2011
17. Perren TJ, Swart AM, Pfisterer J, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484-2496, 2011
18. Aghajanian C, Blank SV, Goff BA, et al: OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039-2045, 2012
19. Bennouna J, Sastre J, Arnold D, et al: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 14:29-37, 2013
20. Monk BJ, Poveda A, Vergote I, et al: A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1. Eur J Cancer 49:S18, 2013 (suppl 3)
21. Naumann RW, Gilbert L, Miller AM, et al: A randomized double-blind phase III trial comparing vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD plus placebo in patients with platinum-resistant ovarian cancer (PROCEED). J Clin Oncol 31, 2013 (suppl 15s; abstr TPS5613)
22. Simpkins F, Belinson JL, Rose PG: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 107:118-123, 2007 (Pubitemid 47464553)
23. Tanyi JL, McCann G, Hagemann AR, et al: Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol 120:464-469, 2011
24. Richardson DL, Backes FJ, Hurt JD, et al: Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol 118:47-51, 2010